Monday, December 23, 2024
HomeTagsDisruptive solutions

disruptive solutions

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer’s Disease

Halozyme Therapeutics, Inc., announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE drug delivery technology, a...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics